IXHL
What one share of Incannex Healthcare holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company developing oral fixed-dose combination therapies and psychedelic-assisted treatments for serious chronic conditions. Our principal development priority is IHL-42X for obstructive sleep apnea.
Incannex Healthcare’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.66 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.10 |
| Cash and investments | $5.40 |
| Book value | $5.37 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$99.60 | $0.62 | −$21.58 | — | $39.36 |
| 2024 | $0.02 | −$34.26 | $0.51 | −$29.92 | — | $19.07 |
| 2025 | $0.07 | −$40.82 | $0.01 | −$10.90 | — | — |
| 2026 | $0.00 | −$1.66 | $0.00 | −$1.10 | — | $5.37 |